Marker of epithelial-mesenchymal transition in pancreatic cancer
In order to elucidate the mechanism of malignant alteration of pancreatic cancer caused by BACH1, changes in the gene expression depending on the expression level of BACH1 in the pancreatic cancer cell line were clarified by RNA sequencing. As a result of experiments on in vitro migration ability and invasion ability and in vivo orthotopic transplantation, BACH1 was found to be used as an excellent biomarker for epithelial-to-mesenchymal transition of pancreatic cancer when used alone or in combination with its downstream regulator FOXA1.
1 . A method of predicting prognosis and treating pancreatic cancer in a subject, the method comprising:
a step of measuring an expression level of a BACH1 gene in a biological sample obtained from a human subject, wherein the biological sample is selected from a group consisting of cells or tissues of the pancreas, cells or tissues around the pancreas, blood or lymph that can contain pancreatic cancer cells, and circulating cancer cells in blood;
a step of predicting the subject as having a poor prognosis of pancreatic cancer by measuring the expression level of the BACH1 gene as being above a cutoff value of the BACH1 expression level calculated from a receiver operating characteristic (ROC) curve; and
a step of performing surgical treatment, radiotherapy, chemotherapy, or endocrine therapy on the subject by the determination of therapeutic strategy based on the results of the prognosis prediction.
2 . A method of predicting prognosis and treating pancreatic cancer in a subject the method comprising;
a step of measuring an expression level of a BACH1 gene and an expression level of FOXA1 in a biological sample obtained from a human subject, wherein the biological sample is selected from a group consisting of cells or tissues of the pancreas, cells or tissues around the pancreas, blood or lymph that can contain pancreatic cancer cells, and circulating cancer cells in blood;
a step of predicting the subject has poor prognosis pancreatic cancer when the subject has an expression level of the BACH1 gene above the cutoff value of the BACH1 expression level calculated from a receiver operating characteristic (ROC) curve and has an expression level of a FOXA1 gene below a cutoff value of the FOXA1 expression level calculated from a receiver operating characteristic (ROC) curve; and
a step of performing surgical treatment, radiotherapy, chemotherapy, or endocrine therapy on the subject when the subject is predicted to have poor prognosis pancreatic cancer.